You have free access to this content

Cancer

Cover image for Vol. 119 Issue 21

1 November 2013

Volume 119, Issue 21

Pages 3739–3896

  1. Issue information

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentary
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Issue information (pages i–viii)

      Version of Record online: 7 DEC 2015 | DOI: 10.1002/cncr.29820

  2. CancerScope

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentary
    5. Original Articles
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
      Big ten universities launch cancer consortium (page 3741)

      Carrie Printz

      Version of Record online: 18 OCT 2013 | DOI: 10.1002/cncr.28428

  3. Commentary

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentary
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Cancer research in the United States: Dying by a thousand paper cuts (pages 3742–3745)

      Hagop Kantarjian, David J. Stewart and Leonard Zwelling

      Version of Record online: 6 JUN 2013 | DOI: 10.1002/cncr.28193

      The authors discuss cancer research in the United States and the implications of bureaucratic burdens on the conduct and cost of research and, consequently, the cost of drugs and health care. They propose potential remedial solutions.

  4. Original Articles

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentary
    5. Original Articles
    6. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer (pages 3746–3752)

      Richard R. Love, Gregory S. Young, Adriano V. Laudico, Nguyen Van Dinh, Gemma B. Uy, Le Hong Quang, Arturo S. De La Peña, Rodney B. Dofitas, Orlino C. Bisquera Jr, Stephen S. S. Siguan, Jonathan D. S. Salvador, Maria Rica Mirasol-Lumague, Narciso S. Navarro Jr, Nguyen Dieu Linh and David Jarjoura

      Version of Record online: 20 AUG 2013 | DOI: 10.1002/cncr.28302

      • image
      • image
      • image

      In premenopausal women, surgical oophorectomy followed by tamoxifen is associated with no loss of bone mineral density in the femoral neck, but modest loss, which stabilizes after 12 months, in the lumbar spine.

    2. Chest and Lung Disease
      You have free access to this content
      Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer (pages 3753–3760)

      Bree R. Eaton, Sungjin Kim, David M. Marcus, Roshan Prabhu, Zhengjia Chen, Suresh S. Ramalingam, Walter J. Curran Jr and Kristin A. Higgins

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28267

      • image
      • image

      In this Surveillance, Epidemiology, and End Results database analysis of patients aged ≥ 70 years with limited-stage small cell lung cancer, the receipt of prophylactic cranial irradiation was found to be an independent predictor of improved patient survival after adjusting for age, race, sex, tumor size, lymph node status, stage of disease, and receipt of thoracic radiotherapy or surgery. Receipt of prophylactic cranial irradiation remained an independent predictor of improved patient survival after further limiting the population to those patients aged ≥ 75 years.

    3. You have free access to this content
      Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: Developing criteria to continue therapy beyond RECIST progression (pages 3761–3768)

      Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Nikhil H. Ramaiya, Hiroto Hatabu, Pasi A. Jänne and Bruce E. Johnson

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28290

      • image
      • image
      • image

      Tumor volume analysis can define volumetric tumor growth after the volume nadir in patients with advanced, epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer who receive EGFR-tyrosine kinase inhibitor therapy. The objective of this tumor growth rate analysis is to provide a quantitative reference value that can be used along with clinical criteria to better aid therapeutic decisions in patients with EGFR-mutant non–small cell lung cancer and to maximize the benefits of effective molecular-targeted therapy.

    4. Gastrointestinal Disease
      You have free access to this content
      Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal (pages 3769–3775)

      Cathy Eng, George J. Chang, Y. Nancy You, Prajnan Das, Yan Xing, Marc Delclos, Robert A. Wolff, Miguel A. Rodriguez-Bigas, John Skibber, Aki Ohinata, Spencer Gould, Jonathan Phillips and Christopher H. Crane

      Version of Record online: 20 AUG 2013 | DOI: 10.1002/cncr.28296

      • image
      • image
      • image

      A retrospective, single-institution analysis of patients receiving concurrent 5-fluorouracil/cisplatin and radiotherapy for locally advanced squamous cell carcinoma (SCC) from 1989 to 2009, with endpoints including clinical complete response rate, local recurrence rate, colostomy-free survival, disease-free survival, overall survival, and treatment-related toxicity. Our data suggest that the combination of 5-fluorouracil and cisplatin with concurrent radiotherapy is an effective treatment for patients with locally advanced SCC of the anal canal.

    5. Gynecologic Oncology
      You have free access to this content
      Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix (pages 3776–3783)

      Alexi A. Wright, Brooke E. Howitt, Andrea P. Myers, Suzanne E. Dahlberg, Emanuele Palescandolo, Paul Van Hummelen, Laura E. MacConaill, Melina Shoni, Nikhil Wagle, Robert T. Jones, Charles M. Quick, Anna Laury, Ingrid T. Katz, William C. Hahn, Ursula A. Matulonis and Michelle S. Hirsch

      Version of Record online: 23 AUG 2013 | DOI: 10.1002/cncr.28288

      • image

      Cervical cancers harbor high rates of potentially targetable oncogenic mutations. In addition, squamous cell carcinoma and adenocarcinoma of the cervix have distinct molecular treatment strategies profiles, suggesting that clinical outcomes may be improved with the use of more tailored treatment strategies, including PI3K and MEK inhibitors.

    6. Hematologic Malignancies
      You have free access to this content
      Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies (pages 3784–3787)

      Ana G. Antun, Shannon Gleason, Martha Arellano, Amelia A. Langston, Morgan L. McLemore, Manila Gaddh, Fuad el Rassi, Leon Bernal-Mizrachi, Jacques Galipeau, Leonard T. Heffner Jr, Elliott F. Winton and Hanna J. Khoury

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28253

      Bleeding is a significant problem in thrombocytopenic patients with hematological malignancies. Epsilon aminocaproic acid is well-tolerated and effective for bleeding prophylaxis in this patient population.

    7. You have free access to this content
      Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL) (pages 3788–3796)

      Tait Shanafelt, Mark C. Lanasa, Timothy G. Call, Anne W. Beaven, Jose F. Leis, Betsy LaPlant, Deborah Bowen, Michael Conte, Diane F. Jelinek, Curtis A. Hanson, Neil E. Kay and Clive S. Zent

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28292

      • image
      • image
      • image

      Ofatumumab-based chemoimmunotherapy (CIT) is well tolerated in patients with previously untreated chronic lymphocytic leukemia. The efficacy of ofatumumab-based CIT compares favorably to historical trials of rituximab-based CIT.

    8. You have free access to this content
      A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 (pages 3797–3804)

      Barbara W. Grant, Sin-Ho Jung, Jeffrey L. Johnson, Lale Kostakoglu, Eric Hsi, John C. Byrd, Jeffrey Jones, John P. Leonard, S. Eric Martin and Bruce D. Cheson

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28299

      • image
      • image
      • image
      • image

      The doublet of rituximab and epratuzumab achieved an 88.2% durable response rate in untreated patients with follicular lymphoma, predicted by FLIPI (Follicular Lymphoma International Prognostic Index) score, with a favorable safety profile. These data support noncytotoxic approaches in these patients.

    9. You have free access to this content
      Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia (pages 3805–3811)

      Paolo Strati, William Wierda, Jan Burger, Alessandra Ferrajoli, Constantine Tam, Susan Lerner, Michael J. Keating and Susan O'Brien

      Version of Record online: 13 AUG 2013 | DOI: 10.1002/cncr.28318

      • image
      • image

      Persistent and new-onset cytopenia after the completion of therapy are a common complication of frontline therapy with fludarabine, cyclophosphamide, and rituximab. Although their presence does not raise concerns about chronic lymphocytic leukemia recurrence or the development of therapy-related myeloid malignancies, it should encourage surveillance for bacterial infections.

    10. Hepatobiliary Disease
      You have free access to this content
      Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma (pages 3812–3820)

      Zhen-Wei Peng, Fu-Rong Liu, Sheng Ye, Li Xu, Yao-Jun Zhang, Hui-Hong Liang, Xiao-Jun Lin, Wan Yee Lau and Min-Shan Chen

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28293

      • image
      • image
      • image

      For elderly patients with hepatocellular carcinoma, radiofrequency ablation might be a better treatment than hepatic resection because of its safety, efficacy, and short hospital stay. Elderly patients with hepatocellular carcinoma ≤ 3 cm in size may be the best candidates to receive radiofrequency ablation.

    11. Melanoma
      You have free access to this content
      Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma (pages 3821–3829)

      Amanda D. Bucheit, Erica Syklawer, John A. Jakob, Roland L. Bassett Jr, Jonathan L. Curry, Jeffrey E. Gershenwald, Kevin B. Kim, Patrick Hwu, Alexander J. Lazar and Michael A. Davies

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28306

      • image

      Certain recurrent mutations in BRAF and NRAS are present in many patients with melanoma. Comparison of patients with advanced melanoma with the most common substitutions (V600E and V600K) in the BRAF gene identified significant differences in demographics, primary tumor characteristics, and clinical outcomes, thereby supporting the presence of mutation-specific clinical differences between different BRAF genotypes.

    12. Neuro-Oncology
      You have full text access to this OnlineOpen article
      Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers (pages 3830–3838)

      Steven Brem, Christina A. Meyers, Gary Palmer, Margaret Booth-Jones, Surbhi Jain and Matthew G. Ewend

      Version of Record online: 23 AUG 2013 | DOI: 10.1002/cncr.28307

      • image
      • image
      • image
      • image

      In this prospective, multicenter, single-arm, phase 2 trial, the authors evaluate the neurocognitive effects of surgery with carmustine chemowafers, while deferring whole-brain radiation therapy, on patients with brain metastases. Patients who undergo surgery with carmustine wafers exhibit improved memory and executive function in the year after surgery.

    13. Discipline

      Disparities Research
      You have free access to this content
      Racial disparities in functional disability among older women with newly diagnosed nonmetastatic breast cancer (pages 3839–3846)

      Cynthia Owusu, Mark Schluchter, Siran M. Koroukian, Suzanne Mazhuvanchery and Nathan A. Berger

      Version of Record online: 23 SEP 2013 | DOI: 10.1002/cncr.28232

      Among older women with newly diagnosed nonmetastatic breast cancer, functional disability is highly prevalent, and African Americans are disproportionately affected.

    14. Epidemiology
      You have free access to this content
      Changes in the availability of screening mammography, 2000–2010 (pages 3847–3853)

      Elena B. Elkin, Coral L. Atoria, Nicole Leoce, Peter B. Bach and Deborah Schrag

      Version of Record online: 13 AUG 2013 | DOI: 10.1002/cncr.28305

      • image
      • image

      Geographic variation in mammography capacity and declines in capacity over time are associated with demographic, socioeconomic, and health care market characteristics. Maldistribution of mammography resources may explain geographic disparities in breast cancer screening rates.

    15. Outcomes Research
      You have free access to this content
      Impact of internet-based cancer survivorship care plans on health care and lifestyle behaviors (pages 3854–3860)

      Christine E. Hill-Kayser, Carolyn C. Vachani, Margaret K. Hampshire, Gloria Di Lullo, Linda A. Jacobs and James M. Metz

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28286

      • image
      • image

      Survivorship care plans are recommended for all cancer survivors by the Institute of Medicine and American College of Surgeons Commission on Cancer; however, their impact on survivors has not been previously assessed. In this article, the authors report on the effectiveness of survivorship care plans with regard to health behaviors, lifestyle, and emotional impact.

    16. You have free access to this content
      Evaluating comparative effectiveness with observational data: Endoscopic ultrasound and survival in pancreatic cancer (pages 3861–3869)

      Abhishek D. Parmar, Kristin M. Sheffield, Yimei Han, Gabriela M. Vargas, Praveen Guturu, Yong-Fang Kuo, James S. Goodwin and Taylor S. Riall

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28295

      • image
      • image
      • image

      A previous observational study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data has suggested that endoscopic ultrasound is associated with improved survival in patients with pancreatic cancer. These authors hypothesized that this finding is due to selection bias, and they used propensity score modeling and instrumental variable analysis to control for this confounding.

    17. You have free access to this content
      Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes (pages 3870–3878)

      Amer M. Zeidan, Steven D. Gore, Diane L. McNally, Maria R. Baer, Franklin Hendrick, Dalia Mahmoud and Amy J. Davidoff

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28298

      • image
      • image

      To the authors' knowledge, the current study is the first report of lenalidomide use in a large Medicare-enrolled population with myelodysplastic syndromes. The authors demonstrate that the “real-life” reductions in red blood cell transfusions were overall consistent with data from clinical trials and were greater when ≥ 3 lenalidomide cycles were received.

    18. You have free access to this content
      Improving colon cancer screening in community clinics (pages 3879–3886)

      Terry Davis, Connie Arnold, Alfred Rademaker, Charles Bennett, Stacy Bailey, Daci Platt, Cristalyn Reynolds, Dachao Liu, Edson Carias, Pat Bass III and Michael Wolf

      Version of Record online: 20 AUG 2013 | DOI: 10.1002/cncr.28272

      Colorectal cancer screening rates using the fecal occult blood test have increased beyond the rates achieved with enhanced usual care by providing literacy-appropriate education with nurse support, but not by providing education alone. More cost-effective alternatives need to be investigated.

    19. Pediatric Oncology
      You have free access to this content
      Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group (pages 3887–3894)

      Eric J. Gratias, Lawrence J. Jennings, James R. Anderson, Jeffrey S. Dome, Paul Grundy and Elizabeth J. Perlman

      Version of Record online: 26 AUG 2013 | DOI: 10.1002/cncr.28239

      • image
      • image
      • image

      Tumor-specific gain of 1q is associated with inferior event-free and overall survival in patients with favorable-histology Wilms tumor and may provide a valuable prognostic marker with which to stratify therapy. A confirmatory study is necessary before this biomarker is incorporated into the risk stratification schema of future therapeutic studies.

  5. Erratum

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentary
    5. Original Articles
    6. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION